Takeda Pharmaceutical Co Ltd (TSE:4502)
円 4205 103 (2.51%) Market Cap: 6.60 Til Enterprise Value: 10.97 Til PE Ratio: 46.05 PB Ratio: 0.90 GF Score: 76/100

Takeda Pharmaceutical Co Ltd Oncology Business Investor and Analyst Seminar Transcript

Feb 25, 2021 / 04:00AM GMT
Release Date Price: 円3610 (+0.14%)
Ayako Iwamuro
Takeda Pharmaceutical Company Limited - Manager of IR and Global Finance

Good afternoon. Thank you very much for your participation in the conference call for seminar on oncology business and its oncology products and disease in Japan. My name Ayako Iwamuro from Takeda Investor Relations.

Before starting, I'd like to remind everyone that we will be discussing forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those discussed today. The factors that could cause our actual results to differ materially are discussed in the most recent Form 20-F and in our other SEC filings.

Please also refer to the important notice on Page 2 of the presentation.

And now please let me introduce today's presenters and panel. Takafumi Horii, Head of Japan Oncology Business Unit; Dr. Kei Hiraoka, Medical Director; Dr. Jumpei Soeda, Head of Japan Medical Affairs; Dr. Akiko Kimura, Senior Medical Director; and Yukari Nishikata, Head of Oncology Therapeutic Area Unit.

First, we'd like

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot